Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY ...
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
Immunotherapies use the power of your immune system to fight your cancer. Vaccines are one form of immunotherapy. Sipuleucel-T is a vaccine used for advanced, metastatic prostate cancer if: It no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results